Unique ID issued by UMIN | UMIN000020937 |
---|---|
Receipt number | R000024122 |
Scientific Title | Analysis of the association between plasma xanthine oxidoreductase activity and atherosclerosis in the patients with metabolic diseases. |
Date of disclosure of the study information | 2016/02/08 |
Last modified on | 2019/08/26 20:42:52 |
Analysis of the association between plasma xanthine oxidoreductase activity and atherosclerosis in the patients with metabolic diseases.
Analysis of the association between plasma xanthine oxidoreductase activity and atherosclerosis in the patients with metabolic diseases.
Analysis of the association between plasma xanthine oxidoreductase activity and atherosclerosis in the patients with metabolic diseases.
Analysis of the association between plasma xanthine oxidoreductase activity and atherosclerosis in the patients with metabolic diseases.
Japan |
Life-style related diseases.(Type 2 diabetes,dyslipidemia,hypertension,obesity)
Endocrinology and Metabolism |
Others
NO
This study attempts to reveal the association between plasmaXOR activity,uric acid, vascular function and states of life-style related diseases,including type2 diabetes,dyslipidemia,hypertension and obesity.
Others
This study attempts to reveal the association between plasmaXOR activity,uric acid, vascular function and states of life-style related diseases,including type2 diabetes,dyslipidemia,hypertension and obesity.
Exploratory
Others
Not applicable
Plasma xanthine oxidoreductase activity
1)body weight,blood pressure
2)uric acid,blood glucose,HbA1c,liver function,lipid parameter(TC,TG,HDL-C,LDL-C)
3)serum creatinine,urinary albumin
4)CAVI:Cardio-ankle vascular index
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1.20 years and over
2.Patients without any hypouricemic agent and who have any of following life-style related diseases.
(3-6)
3.Type 2 diabetes mellitus
HbA1c6.5% and over(untreated)
HbA1c4.8% and over(treated)
4.dyslipidemia
5.hypertension
6.obesity
7.Patients who themselves can voluntarily provide consent to participate in this study
1.Ptients who are judged as inappropriate for inclusion by physicians.
2.Patients who can not be measured CAVI
a.severe arteriosclerosis obliterans
b.arterial fibrillation
500
1st name | Ichiro |
Middle name | |
Last name | Tatsuno |
Toho University Sakura Medical Center
Center of Diabetes,Endocrinology and Metabolism
285-8741
564-1,Shimoshizu,Sakura-City,Chiba
043-462-8811
ichiro.tatsuno@med.toho-u.ac.jp
1st name | Shou |
Middle name | |
Last name | Tanaka |
Toho University Sakura Medical Center
Center of Diabetes,Endocrinology and Metabolism
285-8741
564-1,Shimoshizu,Sakura-City,Chiba
043-462-8811
shou.tanaka@med.toho-u.ac.jp
Toho University Sakura Medical Center
Center of Diabetes,Endocrinology and Metabolism
SANWA KAGAKU KENKYUSHO CO.,LTD
Profit organization
SANWA KAGAKU KENKYUSHO CO.,LTD
not applicable
Toho University Sakura Medical Center
564-1,Shimoshizu,Sakura-City,Chiba
043-462-8811
soumu@sakura.med.toho-u.ac.jp
NO
東邦大学医療センター佐倉病院(千葉県)
2016 | Year | 02 | Month | 08 | Day |
Unpublished
Open public recruiting
2016 | Year | 01 | Month | 15 | Day |
2017 | Year | 03 | Month | 03 | Day |
2016 | Year | 01 | Month | 15 | Day |
2019 | Year | 03 | Month | 31 | Day |
2019 | Year | 03 | Month | 31 | Day |
2019 | Year | 03 | Month | 31 | Day |
2019 | Year | 03 | Month | 31 | Day |
Observational study:cross sectional study
Metabolic syndrome patients
2016 | Year | 02 | Month | 08 | Day |
2019 | Year | 08 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024122